Co-transplantation of Human Ovarian Tissue with Engineered Endothelial Cells: A Cell-based Strategy Combining Accelerated Perfusion with Direct Paracrine Delivery
May 16th, 2018
6.9K views
For some patients, the only option for fertility preservation is cryopreservation of ovarian tissue. Unfortunately, delayed revascularization undermines follicular viability. Here, we present a protocol to co-transplant human ovarian tissue with endothelial cells for utilization as a cell-based strategy combining accelerated perfusion with a direct paracrine delivery of bioactive molecules.
Overview
This protocol describes a method for xenografting cryopreserved human ovarian tissue alongside engineered endothelial cells. This approach aims to enhance re-perfusion and provide paracrine signals to improve follicular activation and viability post-transplant.
Key Study Components
Area of Science
- Reproductive biology
- Tissue engineering
- Cell transplantation
Background
- Cryopreservation of ovarian tissue is a key method for fertility preservation.
- Delayed revascularization can compromise the viability of transplanted follicles.
- Endothelial cells can enhance perfusion and provide necessary growth factors.
- This study explores a combined approach to improve outcomes for ovarian tissue grafts.
Purpose of Study
- To improve post-transplant viability of cryopreserved ovarian tissue.
- To establish a model for studying molecular regulation of folliculogenesis.
- To utilize endothelial cells for dual purposes: mitigating ischemia and delivering bioactive factors.
Methods Used
- Xenografting of cryopreserved ovarian tissue.
- Co-transplantation with engineered endothelial cells.
- Assessment of follicular activation and viability.
- Creation of a fibrin clot for tissue support.
Main Results
- The co-transplantation method enhances tissue viability.
- Endothelial cells provide sustained paracrine signals.
- The approach offers insights into molecular regulators of folliculogenesis.
- Improved re-perfusion is achieved through this combined strategy.
Conclusions
- This protocol presents a novel strategy for ovarian tissue transplantation.
- It highlights the importance of endothelial cells in tissue viability.
- The method can be adapted for further research into follicular development.
Frequently Asked Questions
What is the main goal of this protocol?
The main goal is to improve the viability of cryopreserved ovarian tissue through co-transplantation with endothelial cells.
How do endothelial cells contribute to this method?
Endothelial cells enhance re-perfusion and provide paracrine signals that support follicular activation.
What are the advantages of this technique?
It uses a single vehicle to mitigate ischemia and deliver growth factors, improving overall tissue viability.
What insights can this study provide?
It can offer insights into the molecular regulation of folliculogenesis and factors affecting ovarian tissue health.
What is the significance of creating a fibrin clot?
The fibrin clot provides structural support for the transplanted tissue, aiding in its integration and viability.
Can this method be adapted for other types of tissue?
Yes, the principles of this method may be applicable to other tissue types requiring enhanced viability post-transplant.
Executive Industry Relevance
This protocol addresses a critical bottleneck in fertility preservation: inefficient revascularization of cryopreserved ovarian tissue post-transplant. By co-transplanting engineered endothelial cells that accelerate perfusion and deliver sustained paracrine signals, the method enhances graft viability and follicular development. This integrated approach supports mechanistic de-risking in reproductive therapeutics by enabling controlled interrogation of folliculogenesis regulators.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables functional validation of endothelial-derived paracrine factors in modulating follicular activation and quiescence.
- Operational Value: Provides a reproducible xenograft model to assess molecular regulators of human folliculogenesis.
Screening & Assay Development
- Scientific Value: Generates quantifiable follicular development metrics (volume, antral progression) for compound or cell-based screening.
- Operational Value: Standardizes tissue viability assessment via reduced fibrotic area and increased follicle survival as functional readouts.
Translational & Preclinical Research
- Scientific Value: Supports preclinical evaluation of engineered cell therapies for fertility preservation by linking perfusion to follicular outcomes.
- Operational Value: Establishes a scalable co-transplantation workflow adaptable to other secreted factors beyond AMH.
Pipeline & Workflow Integration
The method fits within the discovery-to-preclinical continuum by enabling hypothesis-driven testing of angiocrine signaling in ovarian grafts, with direct applicability to lead identification in reproductive tissue engineering.
- Discovery Biology: Facilitates pathway clarification through controlled delivery of secreted factors like AMH to assess follicular activation dynamics.
- Screening: Supports assay readiness by generating standardized, vascularized ovarian grafts for evaluating therapeutic candidates.
- Analytics: Provides quantitative outputs including follicular volume, antral follicle counts, and fibrotic area for comparative analysis.
- Translational Research: Bridges discovery and preclinical validation by modeling human folliculogenesis in a physiologically relevant, perfused graft system.
- Enterprise Reuse: Establishes a reusable platform for testing endothelial cell engineering strategies across tissue transplantation contexts.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence in follicular outcomes by reducing ischemic noise and isolating paracrine effects.
- Operational Value: Improves reproducibility through standardized fibrin clot formation and cell dosing protocols.
- Strategic Value: Enables better go/no-go decisions in fertility therapeutic development by validating vascular support mechanisms early.
- Portfolio Impact: Supports risk-adjusted prioritization of candidates that demonstrate synergistic perfusion and signaling benefits.
Implementation Considerations
- Requires expertise in microsurgery, cell culture, and xenograft handling.
- Dependent on sterile surgical facilities and imaging tools (e.g., MRI) for longitudinal follicle tracking.
- Necessitates cross-team standardization between reproductive biology and tissue engineering groups.
- Adaptation to other model systems requires validation of endothelial cell engraftment and paracrine functionality.
- Practical limitations include cell sourcing variability and the need for precise timing between clot formation and tissue placement.
Biopharma FAQs
Why does perfusion assessment matter for ovarian graft validation?
Perfusion assessment determines whether engineered endothelial cells successfully form functional vessels at the graft-host interface, which is critical for mitigating ischemia and supporting follicular survival post-transplant.
How does isolating endothelial cell variables support target validation in folliculogenesis?
By using endothelial cells as a controlled delivery vehicle, the method isolates paracrine signaling effects from ischemic variables, enabling clearer attribution of molecular outcomes to specific secreted factors like AMH.
What quantitative follicular measurements enable go/no-go decisions in fertility therapeutics?
Follicular volume, antral follicle development, and primordial follicle retention provide quantifiable metrics to evaluate whether co-transplantation strategies improve graft functionality and developmental competence.
Why are replication requirements essential for cross-functional reproducibility in tissue engineering?
Replication ensures consistent fibrin clot formation, cell dosing, and surgical engraftment across experiments, which is vital for generating reliable follicular and vascularization data shared between biology and engineering teams.
What statistical analysis is required before implementing this co-transplantation strategy in preclinical studies?
Comparative analysis of follicle counts, fibrotic area, and marker expression between control and experimental grafts is required to validate significant improvements in tissue viability and follicular development attributable to endothelial cell co-transplantation.
Chapters in this video
0:04
Title
1:06
Encapsulation of Ovarian Tissue
3:40
Bilateral Oophorectomy and Co-transplantation of Human Ovarian Tissue with Engineered Endothelial Cells into NSG Mice
5:07
Results: Co-transplantation of Human Ovarian Tissue with Endothelial Cells
6:57
Conclusion
